The Corporation focussed on the biology of healing yesterday announced that it had confirmed its decision to formally pursue Alström syndrome (AS) as a clinical indication for PBI-4050 following positive feedback from its recent meetings with regulatory authorities. These meetings have provided Prometic with clear clinical and regulatory guidance, which will enable the finalisation of the design of a pivotal placebo-controlled Phase 3 clinical trial, including agreement on multiple endpo
06 Dec 2018
Prometic to push ahead with pivotal phase 3 in Alström. No change to guidance on 2019 R&D costs
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prometic to push ahead with pivotal phase 3 in Alström. No change to guidance on 2019 R&D costs
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
06 Dec 2018 -
Author:
Derren Nathan -
Pages:
7
The Corporation focussed on the biology of healing yesterday announced that it had confirmed its decision to formally pursue Alström syndrome (AS) as a clinical indication for PBI-4050 following positive feedback from its recent meetings with regulatory authorities. These meetings have provided Prometic with clear clinical and regulatory guidance, which will enable the finalisation of the design of a pivotal placebo-controlled Phase 3 clinical trial, including agreement on multiple endpo